MiR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn's disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Cheng, Xiuqin ^a   Zhang, Xiaofei ^a,c   Su, Jiewen ^a   Zhang, Yingdi ^a   Zhou, Weimei ^a   Zhou, Jun ^a   Wang, Cheng ^b   Liang, Hongwei ^b   Chen, Xi ^b   Shi, Ruihua ^a   Zen, Ke ^b   Zhang, Chen Yu ^b   Zhang, Hongjie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; CCL20 PROTEIN, HUMAN; CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MICRORNA; MIRN19 MICRORNA, HUMAN; SMALL INTERFERING RNA; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRINITROBENZENESULFONIC ACID; UNTRANSLATED RNA;

3' UNTRANSLATED REGION; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CACO-2 CELL LINE; CHEMICALLY INDUCED; COLITIS; CROHN DISEASE; DOWN REGULATION; DRUG EFFECTS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HT-29 CELL LINE; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MALE; METABOLISM; MIDDLE AGED; MOUSE; NUCLEOTIDE SEQUENCE; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEQUENCE ALIGNMENT;

3' UNTRANSLATED REGIONS; ADULT; ANIMALS; BASE SEQUENCE; CACO-2 CELLS; CHEMOKINE CCL20; CHEMOKINES; COLITIS; CROHN DISEASE; DOWN-REGULATION; FEMALE; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INTESTINAL MUCOSA; MALE; MICE; MICRORNAS; MIDDLE AGED; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; SEQUENCE ALIGNMENT; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRINITROBENZENESULFONIC ACID;

EID: 84930227189     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10397     Document Type: Article

References (43)

1. Kaser, A., Zeissig, S. & Blumberg, R. S. Inflammatory bowel disease. Annu Rev Immunol. 28, 573-621 (2010).
2. Kugathasan, S. & Fiocchi, C. Progress in basic inflammatory bowel disease research. Semin Pediatr Surg. 16, 146-153 (2007).
3. Zidek, Z., Anzenbacher, P. & Kmonickova, E. Current status and challenges of cytokine pharmacology. Br J Pharmacol. 157, 342-361 (2009).
4. Suzuki, A. et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med. 193, 471-481 (2001).
5. Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 7, 454-465 (2007).
6. Liang, Y., Xu, W. D., Peng, H., Pan, H. F. & Ye, D. Q. SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications. Eur J Immunol. 44, 1265-1275 (2014).
7. Trengove, M. C. & Ward, A. C. SOCS proteins in development and disease. Am J Clin Exp Immunol. 2, 1-29 (2013).
8. Larsen, L. & Ropke, C. Suppressors of cytokine signalling: SOCS. Apmis. 110, 833-844 (2002).
9. Tamiya, T., Kashiwagi, I., Takahashi, R., Yasukawa, H. & Yoshimura, A. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol. 31, 980-985 (2011).
10. Ramgolam, V. S. & Markovic-Plese, S. Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis. J Signal Transduct. 2011, 635721 (2011).
11. White, G. E., Cotterill, A., Addley, M. R., Soilleux, E. J. & Greaves, D. R. Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation. J Mol Histol. 42, 137-151 (2011).
12. Maloy, K. J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 474, 298-306 (2011).
13. Peterson, L. W. & Artis, D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 14, 141-153 (2014).
14. Li, Y., de Haar, C., Peppelenbosch, M. P. & van der Woude, C. J. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. Cytokine Growth Factor Rev. 23, 127-138 (2012).
15. Ambros, V. The functions of animal microRNAs. Nature. 431, 350-355 (2004).
16. McKenna, L. B. et al. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology. 139, 1654-1664, 1664.e1651 (2010).
17. Dalal, S. R. & Kwon, J. H. The Role of MicroRNA in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 6, 714-722 (2010).
18. Sonkoly, E. & Pivarcsi, A. Advances in microRNAs: implications for immunity and inflammatory diseases. J Cell Mol Med. 13, 24-38 (2009).
19. Pauley, K. M., Cha, S. & Chan, E. K. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 32, 189-194 (2009).
20. Fasseu, M. et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One. 5, e13160 (2010).
21. Zhou, C., Cunningham, L., Marcus, A. I., Li, Y. & Kahn, R. A. Arl2 and Arl3 regulate different microtubule-dependent processes. Mol Biol Cell. 17, 2476-2487 (2006).
22. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116, 281-297 (2004).
23. Pastorelli, L., De Salvo, C., Mercado, J. R., Vecchi, M. & Pizarro, T. T. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol. 4, 280 (2013).
24. Perron, M. P., Boissonneault, V., Gobeil, L. A., Ouellet, D. L. & Provost, P. Regulatory RNAs: future perspectives in diagnosis, prognosis, and individualized therapy. Methods Mol Biol. 361, 311-326 (2007).
25. Zhu, S., Pan, W. & Qian, Y. MicroRNA in immunity and autoimmunity. J Mol Med (Berl). 91, 1039-1050 (2013).
26. Coskun, M., Bjerrum, J. T., Seidelin, J. B. & Nielsen, O. H. MicroRNAs in inflammatory bowel disease-pathogenesis, diagnostics and therapeutics. World J Gastroenterol. 18, 4629-4634 (2012).
27. Han, H. et al. Differentiated miRNA expression and validation of signaling pathways in apoE gene knockout mice by crossverification microarray platform. Exp Mol Med. 45, e13 (2013).
28. Li, Y. et al. Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulcerative colitis. Inflamm Bowel Dis. 19, 132-140 (2013).
29. Kwon, J. H., Keates, S., Bassani, L., Mayer, L. F. & Keates, A. C. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut. 51, 818-826 (2002).
30. Keates, S., Han, X., Kelly, C. P. & Keates, A. C. Macrophage-inflammatory protein-3alpha mediates epidermal growth factor receptor transactivation and ERK1/2 MAPK signaling in Caco-2 colonic epithelial cells via metalloproteinase-dependent release of amphiregulin. J Immunol. 178, 8013-8021 (2007).
31. Liu, S. Q., Jiang, S., Li, C., Zhang, B. & Li, Q. J. miR-17-92 cluster targets phosphatase and tensin homology and Ikaros Family Zinc Finger 4 to promote TH17-mediated inflammation.J Biol Chem. 289, 12446-12456 (2014).
32. Jiang, R. et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 54, 900-909 (2011).
33. Ansari,S. et al. Immobilization of murine anti-BMP-2 monoclonal antibody on various biomaterials for bone tissue engineering. Biomed Res Int. 2014, 940860 (2014).
34. Jiang, R. et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer. 13, 59 (2013).
35. Pei, J., Fu, W., Yang, L., Zhang, Z. & Liu, Y. Oxidative stress is involved in the pathogenesis of Keshan disease (an endemic dilated cardiomyopathy) in China. Oxid Med Cell Longev. 2013, 474203 (2013).
36. Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian microRNA targets. Cell. 115, 787-798 (2003).
37. Krek, A. et al. Combinatorial microRNA target predictions. Nat Genet. 37, 495-500 (2005).
38. Betel, D., Wilson, M., Gabow, A., Marks, D. S. & Sander, C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 36, D149-153 (2008).
39. Cao, M. et al. miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor. Eur J Cancer. 50, 1013-1024 (2014).
40. Kwon, J. H., Keates, S., Bassani, L., Mayer, L. F. & Keates, A. C.Colonic epithelial cells are a major site of macrophage inflammatory protein 3a (MIP-3a ) production in normal colon and inflammatory bowel disease. Gut. 51, 818-826 (2002).
41. Zuo, L. et al. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut. 59, 470-479 (2010).
42. Arab, H. H., Al-Shorbagy, M. Y., Abdallah, D. M. & Nassar, N. N. Telmisartan Attenuates Colon Inflammation, Oxidative Perturbations and Apoptosis in a Rat Model of Experimental Inflammatory Bowel Disease. PLoS One. 9, e97193 (2014).
43. Huang, Z. et al. miR-141 Regulates colonic leukocytic trafficking by targeting CXCL12beta during murine colitis and human Crohn's disease. Gut. 63, 1247-1257 (2014).